Develops small-molecule drug candidates targeting the gene-control system for patients with cancer and immune and inflammatory diseases.
10-K for FY2025, filed Mar 11, 2026
Foghorn earns collaboration revenue from partners for licenses and drug-discovery and development work. Agreements can include upfront payments, development milestones and royalties tied to partner sales.
10-K for FY2025, filed Mar 11, 2026On December 10, 2021, we entered into a collaboration agreement (the “Lilly Collaboration Agreement”) with Eli Lilly and Company (“Lilly”)…View ↗
The Lilly Collaboration Agreement generally provides that Lilly and Foghorn will co-develop and co-commercialize certain “joint” programs…View ↗
The Company assesses the goods or services promised within each contract and determines those that are performance obligations. The…View ↗
If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered…View ↗
For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level…View ↗
$30.9M
10-K for FY2025, filed Mar 11, 2026
$30.9M ↗Lilly is the customer for Foghorn’s collaboration work, including joint oncology development and platform-based discovery programs.
No. It lost $74.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
$58.2MView ↗
8-K, filed Oct 1, 2026
WATERTOWN, Mass. -- (GLOBE NEWSWIRE) – October 1, 2026 – Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a…View ↗
Growing. Revenue grew 23.4x in 4 years, from $1.3M in FY2021 to $30.9M in FY2025, about 120% a year.
Clinical pipeline focus
The older report described clinical-stage cancer drug candidates; the latest report centered development on a Lilly-partnered candidate and described the other candidates as preclinical.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 11, 2026Our two clinical-stage candidates are being studied across multiple indications and are supported by compelling science and preclinical…View ↗
Competes with Arvinas, C4 Therapeutics, Kymera Therapeutics, Nurix Therapeutics, Amphista, CellCentric, IDEAYA Biosciences, Novartis, Plexium, Opna Bio, Relay Therapeutics, SK Bio, and Tolremo Therapeutics
10-K for FY2025, filed Mar 11, 2026We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the development of therapies…View ↗
Loading...